KYNB — KYNTRA BIO, INC.

Nasdaq · Health Care · Pharmaceuticals · CIK 921299 ·
Last close
$6.85
Market Cap
$27.73M
52W High
$7.65
52W Low
$6.32
ADV30
7,968
Next earnings
2026-08-10
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 3,738,000 -368,000 -13,796,000 -15,198,000 109,629,000 36,997,000 118,919,000
Dec 2025 1,277,000 999,000 -13,519,000 -14,220,000 119,594,000 47,872,000 115,119,000
Sep 2025 1,076,000 1,134,000 -5,370,000 200,636,000 137,014,000 117,975,000 119,529,000
Jun 2025 1,348,000 1,263,000 -11,659,000 -7,603,000 178,055,000 23,367,000 359,085,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-4,774,000
Investing CF
$35,419,000
Financing CF
$-86,028,000
CapEx
$-179,000
Dividends Paid
Buybacks
EPS Diluted TTM
$45.47
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,706,047,000
Inventory
$3,743,000
Receivables
$4,216,000
ST Investments
$41,106,000
EBIT TTM
$-49,533,000
Pretax Income TTM
$-58,295,000
Interest Exp TTM
$8,762,000
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$7,439,000
EBITDA
$-43,736,000
Free Cash Flow
Enterprise Value
$-5,186,470
Total Cash
$87,237,000
Total Debt
$19,249,000
Shares Out
4,048,112
Trailing EPS
$-13.99
Book Value
$-10.82
ROE
ROA
-20.2%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 6,440,000 -45,342,000 183,452,000 119,594,000 115,119,000 -4,774,000
Dec 2024 29,621,000 -130,962,000 -47,579,000 214,525,000 398,160,000 -137,999,000
Dec 2023 46,803,000 -310,115,000 -284,232,000 423,529,000 585,728,000 -315,021,000
Dec 2022 140,734,000 -301,025,000 -293,654,000 610,087,000 611,567,000 -145,933,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-9.73

Peers — same industry

TickerNameMarket CapLastDaily %
BRNS Barinthus Biotherapeutics plc. $27.84M $0.68
CRVO CervoMed Inc. $28.24M $3.05
RMHI Retrieve Medical Holdings, Inc. $27.18M $1.00
IGC IGC Pharma, Inc. $28.55M $0.29
GRDX GridAI Technologies Corp. $28.58M $4.61

News headlines (Yahoo Finance, 1h cache)

Kyntra Bio Inc (KYNB) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic Advances ...
2026-05-12 07:07 · Yahoo
Kyntra Bio (KYNB) Q1 2026 Earnings Transcript
2026-05-11 22:10 · Yahoo
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates
2026-05-11 22:05 · Yahoo
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-11 20:05 · Yahoo
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates
2026-05-07 12:50 · Yahoo
Kyntra Bio to Report First Quarter 2026 Financial Results
2026-05-04 20:05 · Yahoo
Replays from RedChip's Biotech Investor Conference Now Available
2026-04-20 15:00 · Yahoo
Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know
2026-04-14 16:00 · Yahoo
RedChip's April 16 Virtual Investor Conference to Highlight Companies Driving the Next Wave of Biotech Innovation
2026-04-10 16:55 · Yahoo
Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
2026-04-08 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.